New strategies for relapsed acute myeloid leukemia: Fertile ground for translational research

Shira N. Dinner*, Francis J. Giles, Jessica K. Altman

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations

Abstract

Purpose of review Although frontline treatment of acute myeloid leukemia (AML) achieves high remission rates, approximately 75-80% of patients will either not respond to or relapse after initial therapy. Some patients, generally those who are younger, can be successfully salvaged with second-line chemotherapy followed by allogeneic stem cell transplantation. There is a great need for novel therapies in AML. Recent findings Advances in molecular technology recently identified recurrent mutations including mutations of DNMT3A, IDH1/2, and TET2. These mutations represent a major advance in the understanding of leukemogenesis and prognosis, and have enabled the development of targeted therapies. Summary Improved knowledge of the molecular pathogenesis of AML has allowed development of therapies targeting epigenetic modulation, intracellular signaling pathways, prosurvival proteins, and the tumor microenvironment.

Original languageEnglish (US)
Pages (from-to)79-86
Number of pages8
JournalCurrent Opinion in Hematology
Volume21
Issue number2
DOIs
StatePublished - Mar 1 2014

Keywords

  • Acute myeloid leukemia
  • Epigenetic modulation
  • Intracellular signaling pathways
  • Tumor microenvironment

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'New strategies for relapsed acute myeloid leukemia: Fertile ground for translational research'. Together they form a unique fingerprint.

Cite this